Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
- Trial name
- NCT04093752
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 67 sites in Australia, China and 2 more
- Volunteers
- 917 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Chronic Kidney Disease
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
- Trial name
- AWARD-7 (NCT01621178)
- Testing
- Dulaglutide, Insulin glargine, Insulin lispro
- Where
- 89 sites in United States, Brazil and 7 more
- Volunteers
- 577 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes
It is a phase II, randomized, double-blind, placebo-controlled study of P2202 in patients of type 2 diabetes mellitus, inadequately controlled with a stable dose of metformin or sulfonylurea or both.
- Trial name
- NCT01674348
- Testing
- P2202
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Piramal Enterprises Limited
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
The objective of the study is to test the efficacy, safety and tolerability of several doses of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks together with metformin in patients with type 2…
- Trial name
- NCT00309608
- Testing
- Linagliptin, Glimepiride
- Where
- 48 sites in France, Germany and 4 more
- Volunteers
- 333 people
- Sponsor
- Boehringer Ingelheim
Diabetes
Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients
The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.
- Trial name
- NCT00461617
- Testing
- Mitiglinide
- Volunteers
- 291 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in…
- Trial name
- NCT00996658
- Testing
- Linagliptin
- Where
- 52 sites in United States, France and 2 more
- Volunteers
- 278 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes, Hypertension
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
- Conditions
- Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
- Trial name
- iCaReMe (NCT03549754)
- Where
- 76 sites in Brazil, Chile and 18 more
- Volunteers
- 35,000 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
The Mobile Diabetes Mgmt. Study With Type 2 Diabetes
A Multi-center, Randomized, Parallel, Open Clinical Trial to Evaluate the Glycemic Control Effect of the Mobile Healthcare Service Using U-Healthcare Clinical Decision Support System (CDSS) and U-Healthcare Gateway in Patients…
- Trial name
- NCT02451631
- Testing
- Traditional care with paper, Health-on G App. + Physician Web
- Where
- 3 sites in South Korea
- Volunteers
- 184 people
- Sponsor
- Healthconnect
Diabetes Mellitus, Type 2
A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy
The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes a test formulation of insulin lispro and the effect of the test formulation on blood sugar…
- Trial name
- NCT02623465
- Testing
- Insulin Lispro
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
The purpose of this study is to assess the hypothesis that treatment with study medication (omarigliptin; MK-3102) provides greater reduction in A1C Hemoglobin (a marker of diabetic severity) compared with placebo, after 12 weeks…
- Trial name
- NCT01217073
- Testing
- Omarigliptin, Pioglitazone, Metformin
- Volunteers
- 685 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study evaluates the addition of dapagliflozin in the treatment of type 2 diabetes with metformin and evogliptin combination therapy.
- Trial name
- NCT04356742
- Testing
- Dapagliflozin 10mg, Evogliptin 5mg, Metformin≥1000mg
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure in the routine clinical setting.
- Trial name
- NCT04285983
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes
- Trial name
- NCT01475461
- Testing
- PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg
- Where
- 63 sites in United States, Hungary and 6 more
- Volunteers
- 345 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia
This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Indonesia.
- Trial name
- DiabCare Asia (NCT01934686)
- Testing
- No treatment given
- Where
- Indonesia
- Volunteers
- 1,862 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
The purpose of this study is to evaluate the efficacy and safety of co-administration of Canagliflozin (TA-7284) and Teneligliptin (MP-513) once daily for 24 weeks in Japanese patients with Type 2 diabetes mellitus who are…
- Trial name
- NCT02354222
- Testing
- Canagliflozin, Teneligliptin
- Where
- 3 sites in Japan
- Volunteers
- 154 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
The objective of the current study is to investigate the efficacy, safety and tolerability of several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes…
- Trial name
- NCT00328172
- Testing
- BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily
- Where
- 71 sites in United States, Australia and 4 more
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM
This study was designed as a non-interventional, single-group, open-label, multicenter observational study for patients with type 2 diabetes in the real world clinical setting.
- Trial name
- SSUG (NCT04267601)
- Testing
- Anagliptin
- Where
- South Korea
- Volunteers
- 2,448 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes Mellitus
Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus
The purpose of this study is to compare the efficacy of Amaryl®M 1/500 mg twice daily versus Amaryl® 4 mg both in combination with Lantus® once-daily regimen in type 2 Diabetes Mellitus patients with inadequate glycemic control.
- Trial name
- NCT00913367
- Testing
- glimepiride + insulin glargine (Amaryl + Lantus), glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Handok Inc.
Essential Hypertension, Diabetes Mellitus, Type 2
Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
The purpose of this study is to evaluate safety and efficacy of ATB-1011 and ATB-1012 co-administration in patients with essential hypertension and type II diabetes mellitus
- Trial name
- NCT05573477
- Testing
- ATB-1011, ATB-1012, ATB-1013
- Where
- South Korea
- Volunteers
- 255 people
- Sponsor
- Autotelicbio
Diabetes Mellitus Type 2
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00111670
- Testing
- DPP-IV Inhibitor
- Where
- 40 sites in United States, Bulgaria and 7 more
- Volunteers
- 291 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.